MedTrace Logo

Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life

NCT01595724 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3006

Last updated 2015-07-10

No results posted yet for this study

Summary

The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life. These data will be collected using a special patient questionnaire (Endometriosis Health Profile 5, EHP-5). The study will also be used to describe the basic disease status and demographic characteristics of patients searching treatment by a gynecologist because of their endometriosis. In addition, the study will give insight into the typical diagnostic measures the physicians in different countries are using in the field of endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Visanne (Dienogest, BAY86-5258)

Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-07-31
Completion
2015-05-31

Countries

  • Belarus
  • Egypt
  • Jordan
  • Kazakhstan
  • Kuwait
  • Lebanon
  • Qatar
  • Russia
  • Saudi Arabia
  • Ukraine
  • United Arab Emirates

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01595724 on ClinicalTrials.gov